<DOC>
	<DOCNO>NCT00244127</DOCNO>
	<brief_summary>To evaluate safety efficacy R-COMP elderly patient advance aggressive NHL . Myocet ( non-pegylated liposomal doxorubicin ) replace conventional doxorubicin R-CHOP regimen .</brief_summary>
	<brief_title>Open Label , Single Arm , Phase II Study Using R-COMP Elderly Patients With Aggressive NHL .</brief_title>
	<detailed_description>To evaluate duration remission , disease free survival 2-year survival R-COMP first line therapy elderly patient advance aggressive NHL . To evaluate tolerability R-COMP first line therapy elderly patient advance aggressive NHL .</detailed_description>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Diffuse Large BCell Lymphoma ( DLBCL ) , morphologic variant subtypes , i.e . Centroblastic lymphoma , Immunoblastic lymphoma , Tcell rich/Bcell lymphoma , anaplastic large Bcell lymphoma , mediastinal ( thymic ) large Bcell lymphoma ; Primary diffuse large Bcell lymphoma MALT ( incorrectly define highgrade MALT lymphoma ) ; Marginal zone Bcell lymphoma coexist area DLBCL ; Age ≥60 year ; Clinical stage diagnosis : I A bulky – IV B ; CD20 positivity ; Serum negativity HbsAg HCV except sign active viral replication , assess HCVRNA copy ; Absolute neutrophil count ( ANC ) ≥1.5x109/L , platelet count ≥100x109/L ( unless attribute directly bone marrow involvement lymphoma autoimmune disease secondary lymphoma ) ; Serum creatinine ≤130μM/L , serum bilirubin ≤2.5xULN aspartate aminotransferase ( AST/GOT ) , ≤2.5xULN alanine aminotransferase ( ALT/GPT ) ≤2.5xULN , alkaline phosphatase ≤4 time upper limit normal ( unless increase attribute directly presence tumour Investigator ) Left ventricular ejection fraction ( LVEF ) ≥50 % ; ECOG performance status 02 ; At least one measurable lesion mandatory ; Written inform consent give time registration ; Males female ( male females childbearing potential must agree use adequate contraception duration , 3 month completion , treatment ) . Clinical stage I nonbulky , CS IIA less three site disease involve ( patient stage IIB eligible , regardless number site involve ) ; Tumour involvement CNS ; Indolent lymphoma transform aggressive histological type , even never previously treat ; Mantle Cell Lymphoma , Peripheral T cell Lymphoma variant ; Aggressive nonHodgkin ’ lymphoma transplant patient ; Clinically significant secondary cardiovascular disease , e.g . uncontrolled hypertension , ( rest diastolic blood pressure &gt; 115 mmHg ) , uncontrolled multifocal cardiac arrhythmia , symptomatic angina pectoris congestive cardiac failure NYHA class IIIIV ; Evidence severe active acute chronic infection ; Concurrent malignancy history malignancy , except basal cell carcinoma skin ( BCC ) insitu cervical carcinoma ( CIN ) / Myelodysplastic syndrome ; HbsAg , HIVpositive , HCVRNApositive patient ; Inability comply study procedure ; Prior CNS lymphoma ; Prior radiation nonCNS lymphoma mass ( es ) treatment lymphoma ; History allergic reaction anthracyclines , egg , egg product know sensitivity , history unusual reaction , component , treatment similar , investigational treatment regimen ; Presence medication may interfere study treatment action investigational product confuse assessment study result Pregnant woman nurse mother ; Participation investigational drug study within 4 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
</DOC>